Efficacy and safety of Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity, a systematic review and meta analysis
Table 1: Study Characteristics
Author, Year Study Design Sample Size Intervention Comparator Objectives Follow up Outcomes Measured Inclusion and exclusion criteria
Patricia J. Rodriguez, et al. 2024
cohort study Total: 18 386 (After propensity match)
tirzepatide: 9193; semaglutide: 9192 Tirzepatide: Initial dose of 5 mg
Semaglutide: Initial dose of 0.25 mg
(with dose escalation every 4 weeks to reach the target maintenance dose) Tirzepatide Vs Semaglutide on-treatment weight loss and rates of gastrointestinal adverse events Mean days : 165 Weight loss: ≥5%, ≥10%, ≥15% (hazard ratios);
Percentage weight change;
Gastrointestinal AEs: Hazard ratios. IC: New users of drugs with with overweight (BMI ≥27) or obesity (BMI ≥3; no prior GLP-1 RA use
EC: History of severe gastrointestinal AEs
Table 2: Efficacy Outcomes
Author, Year Baseline weight
% Weight change % Achieving ≥5% Weight Loss
% Achieving ≥10% Weight Loss % Achieving ≥15% Weight Loss BMI lipid profiles changes
Patricia J. Rodriguez, et al. 2024 Baseline weight:
Tirzepatide: 110 (25.7) kg
Semaglutide: 109 (25.2) kg
(End point not measured) 3 months:
• Tirzepatide: −5.9% (95% CI, −6.0% to −5.8%)
• Semaglutide: −3.6% (95% CI, −3.7% to −3.4%)
6 months:
• Tirzepatide: −10.1% (95% CI, −10.4% to −9.9%)
• Semaglutide: −5.8% (95% CI, −6.0% to −5.5%)
At 12 months:
• Tirzepatide: −15.3% (95% CI, −16.0% to −14.5%)
• Semaglutide: −8.3% (95% CI, −9% to −7.6%)
Tirzepatide: 81.8% (95% CI, 79.8%-83.7%
Semaglutide: 66.5% (95% CI, 64.3%-68.7%) Tirzepatide: 62.1% (95% CI, 59.7%-64.3%)
Semaglutide: 37.1% (95% CI, 34.6%-39.4%) Tirzepatide: 42.3% (95% CI, 39.8%-44.6%)
Semaglutide: 18.1% (95% CI, 16.1%-20.0%) Not measured Not measured
Table 3: Safety outcomes
Author, Year Adverse events Serious Adverse events Drug Discontinuation Rate Other side effects
Conclusion
Patricia J. Rodriguez, et al. 2024 No significant differences in the risk of gastrointestinal adverse events (AEs) Not reported Tirzepatide: 5140 [55.9%];
semaglutide: 4823 [52.5%] Not reported In the population of adults with overweight or obesity, use of tirzepatide was associated with significantly greater weight loss than semaglutide.
